Immix Biopharma (NASDAQ:IMMX) Rating Lowered to “Sell” at Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

A number of other research analysts have also issued reports on the stock. Citizens Jmp began coverage on shares of Immix Biopharma in a report on Monday, March 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Finally, Mizuho started coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Immix Biopharma currently has an average rating of “Hold” and an average price target of $15.00.

Immix Biopharma Stock Down 1.1%

Shares of NASDAQ:IMMX opened at $10.00 on Friday. The company has a market capitalization of $529.60 million, a P/E ratio of -12.99 and a beta of 0.25. Immix Biopharma has a 52-week low of $1.34 and a 52-week high of $10.71. The stock’s fifty day simple moving average is $6.87 and its 200-day simple moving average is $4.76.

Institutional Trading of Immix Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP acquired a new position in shares of Immix Biopharma during the 2nd quarter valued at about $52,000. Vanguard Group Inc. boosted its position in shares of Immix Biopharma by 4.5% in the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after acquiring an additional 31,625 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after acquiring an additional 10,950 shares during the last quarter. Imprint Wealth LLC purchased a new stake in Immix Biopharma in the third quarter valued at approximately $141,000. Finally, Citadel Advisors LLC acquired a new position in Immix Biopharma during the third quarter worth approximately $188,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.